Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake
調査の概要
状態
条件
詳細な説明
Research suggests that a connection between vitamin D and MS could be tied to the positive effects vitamin D has on the immune system. Published data also shows a synergistic effect of vitamin D in conjunction with Glatiramer acetate (GA), an already approved FDA immunomodulating drug, in the treatment of multiple sclerosis. Further correlation of vitamin D and GA or Interferon Beta needs to be tested.
This is a retrospective pilot study in which 100 patients diagnosed with relapsing-remitting MS (RR-MS) according to the McDonald criteria and treated with either GA or interferon with and without vitamin D supplementation for at least 2 years were included. Only RR-MS patients who received FDA approved immuno-modulatory drugs for MS are included in this review.
Relapses before and during treatment will be analyzed and a subgroup analysis will be done on those who received vitamin D and those who did not. Magnetic resonance Imaging (MRI) of the brain and cervical spine of these MS patients will also be reviewed to see if there is any correlation between radiologic changes, relapses and vitamin D level.
The 100 MS patients involved the chart review will be invited to participate in a one time blood draw to measure vitamin D levels. Additionally, the MS patients will be asked about their relapse status and medication history.
Twenty (20) healthy individuals not on vitamin D supplementation will be used as controls to get a baseline vitamin D level.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Illinois
-
Peoria、Illinois、アメリカ、61637
- OSF Saint Francis Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
MS Group: Relapsing-remitting MS (RR-MS) patients according to the McDonald criteria who are treated with a FDA approved immuno-modulatory drugs.
Control Group: Healthy individuals not on vitamin D supplementation.
説明
Inclusion Criteria:
Inclusion Criteria (MS Group):
- Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
- Be age 18 or older at the time of informed consent.
- Have a diagnosis of relapsing-remitting multiple sclerosis (RR-MS) as defined by the McDonald Criteria.
- Are taking FDA approved immune-modulatory drugs for MS.
- Patients had at least one relapse during the year prior to initiation of MS treatment.
- After at least 2 years on therapy, patients were classified as MS responders (MS-R) or MS non-responders (MS-NR) based on a clinical criteria recently reported in the literature. A responder (MS-R) is a patient with an annual relapse rate (ARR) < 0.5 and no evidence of disease progression as measured by EDSS (expanded disability status scale). A hypo/non-responder (MS-NR) is a patient with an ARR > 0.5 and/or with progression in the EDSS of at least 1 point sustained for 6 months.
Inclusion Criteria (Control Group):
- Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
- Be age 18 or older at the time of informed consent.
- Have not taken any vitamin D supplementation for more than 12 months.
Exclusion Criteria:
Exclusion Criteria (MS Group):
- Those who have a diagnosis of secondary progressive MS (SPMS) or primary progressive MS (PPMS).
- Unwillingness or inability to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the study protocol.
- Any other condition, clinical finding, or reason that, in the opinion of the Investigator, is determined to be unsuitable for enrollment into this study.
- Those who received other forms of treatment under than a FDA approved MS drugs are excluded.
Exclusion Criteria(Control Group):
- Unwillingness or inability to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the study protocol.
- History of osteoporosis, kidney disease, parathyroid disease, problems with calcium metabolism, sacrcoidosis, and/or pregnancy.
- Current nursing home or bed bound patients.
- Any other condition, clinical finding, or reason that, in the opinion of the Investigator, is determined to be unsuitable for enrollment into this study.
Inclusion Criteria (Retrospective Chart Review) • Only RR-MS patients who received FDA approved immuno-modulatory drugs for MS.
Exclusion Criteria (Retrospective Chart Review)
• Patients diagnosed with MS sub-types other than RR-MS.
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
---|
Control Group (Vitamin D level)
Twenty (20) healthy individuals not on vitamin D supplementation will be used as controls to get a baseline vitamin D level.
|
MS Group
RR-MS patients treated with a FDA approved immuno-modulatory drug with and without vitamin D supplementation for at least 2 years.
|
Retrospective Chart Review
RR-MS patients treated with a FDA approved immuno-modulatory drug for MS.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
• Annual relapse rates
時間枠:After at least 2 years on therapy with an approved immuno-modulatory drug for MS.
|
Data collected from retrospective chart review part of study
|
After at least 2 years on therapy with an approved immuno-modulatory drug for MS.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Expanded Disability Status Scale
時間枠:After at least 2 years on therapy with an approved immuno-modulatory drug for MS.
|
Data collected from retrospective chart review part of study.
|
After at least 2 years on therapy with an approved immuno-modulatory drug for MS.
|
Multiple Sclerosis Responders
時間枠:After at least 2 years on therapy with an approved immuno-modulatory drug for MS.
|
Data collected from retrospective chart review part of study.
|
After at least 2 years on therapy with an approved immuno-modulatory drug for MS.
|
Multiple Sclerosis Non-Responders
時間枠:After at least 2 years on therapy with an approved immuno-modulatory drug for MS.
|
Data collected from retrospective chart review part of study.
|
After at least 2 years on therapy with an approved immuno-modulatory drug for MS.
|
Response to immunodulators among patients who received MS treatment with or without vitamin D
時間枠:After at least 2 years on therapy with an approved immuno-modulatory drug for MS.
|
Data collected from retrospective chart review part of study.
|
After at least 2 years on therapy with an approved immuno-modulatory drug for MS.
|
non-response to immunodulators among patients who received MS treatment with or without vitamin D
時間枠:After at least 2 years on therapy with an approved immuno-modulatory drug for MS.
|
Data collected from retrospective chart review part of study.
|
After at least 2 years on therapy with an approved immuno-modulatory drug for MS.
|
MRI (brain images)
時間枠:after at least 2 years on therapy with an approved immuno-modulatory drug for MS.
|
Data collected from retrospective chart review part of study.
|
after at least 2 years on therapy with an approved immuno-modulatory drug for MS.
|
その他の成果指標
結果測定 |
時間枠 |
---|---|
Serum Vitamin D levels in subjects taking GA with Vitamin D supplementation.
時間枠:Within 30 days of consent or when patient is able
|
Within 30 days of consent or when patient is able
|
Serum Vitamin D levels in subjects taking GA without Vitamin D supplementation
時間枠:Within 30 days of consent or when patient is able
|
Within 30 days of consent or when patient is able
|
Serum vitamin D levels in subjects taking Interferon Beta with vitamin D supplementation
時間枠:Within 30 days of consent or when patient is able
|
Within 30 days of consent or when patient is able
|
Serum vitamin D levels in subjects taking Interferon Beta without vitamin D supplementation
時間枠:Within 30 days of consent or when patient is able
|
Within 30 days of consent or when patient is able
|
serum vitamin D levels from the control group
時間枠:Within 30 days of consent or when patient is able
|
Within 30 days of consent or when patient is able
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Reuben M Valenzuela, MD、OSF HealthCare System
出版物と役立つリンク
一般刊行物
- D'hooghe MB, Haentjens P, Nagels G, Garmyn M, De Keyser J. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis. Mult Scler. 2012 Apr;18(4):451-9. doi: 10.1177/1352458511423778. Epub 2011 Sep 27.
- Smolders J, Moen SM, Damoiseaux J, Huitinga I, Holmoy T. Vitamin D in the healthy and inflamed central nervous system: access and function. J Neurol Sci. 2011 Dec 15;311(1-2):37-43. doi: 10.1016/j.jns.2011.07.033. Epub 2011 Aug 23.
- O'Connor K, Weinstock-Guttman B, Carl E, Kilanowski C, Zivadinov R, Ramanathan M. Patterns of dietary and herbal supplement use by multiple sclerosis patients. J Neurol. 2012 Apr;259(4):637-44. doi: 10.1007/s00415-011-6226-3. Epub 2011 Sep 6.
- Weinstock-Guttman B, Zivadinov R, Ramanathan M. Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. J Neurol Sci. 2011 Dec 15;311(1-2):86-91. doi: 10.1016/j.jns.2011.07.024. Epub 2011 Aug 16.
- McDowell TY, Amr S, Culpepper WJ, Langenberg P, Royal W, Bever C, Bradham DD. Sun exposure, vitamin D intake and progression to disability among veterans with progressive multiple sclerosis. Neuroepidemiology. 2011;37(1):52-7. doi: 10.1159/000329258. Epub 2011 Aug 5.
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- OSF-13-002
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。